Literature DB >> 8447745

Interferon-associated retinopathy.

D R Guyer1, J Tiedeman, L A Yannuzzi, J S Slakter, D Parke, J Kelley, R A Tang, M Marmor, G Abrams, J W Miller.   

Abstract

Interferon alfa is used to treat various systemic disorders and recently has been suggested as a possible treatment for choroidal neovascularization. We report 10 cases of retinal ischemia associated with the use of interferon alfa for various illnesses. The retinal findings include cotton-wool spot formation, capillary nonperfusion, arteriolar occlusion, and hemorrhage. The retinal complications may sometimes be reversible when treatment is stopped. Our findings emphasize the need to have patients who are receiving interferon alfa therapy monitored for these retinal complications, which may rarely be associated with permanent loss of vision secondary to closure of retinal capillaries.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8447745     DOI: 10.1001/archopht.1993.01090030068041

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  42 in total

Review 1.  Tolerability of treatments for viral hepatitis.

Authors:  A Gervais; N Boyer; P Marcellin
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

2.  Severe interferon associated retinopathy.

Authors:  K L Tu; J Bowyer; K Schofield; S Harding
Journal:  Br J Ophthalmol       Date:  2003-02       Impact factor: 4.638

3.  [Anterior ischemic optic neuropathy and retinopathy during systemic interferon therapy].

Authors:  M Moerchen; A-K Rowton; K-H Emmerich
Journal:  Ophthalmologe       Date:  2007-08       Impact factor: 1.059

4.  Symptomatic interferon retinopathy successfully treated by hypertension management.

Authors:  C Han; J O'Day
Journal:  Br J Ophthalmol       Date:  2007-09       Impact factor: 4.638

Review 5.  Ophthalmologic complications of antiviral therapy in hepatitis C treatment.

Authors:  Roderick O'Day; Mark C Gillies; Golo Ahlenstiel
Journal:  World J Gastroenterol       Date:  2013-12-07       Impact factor: 5.742

6.  Pegylated interferon alpha-associated optic neuropathy.

Authors:  Kathleen T Berg; Bruce Nelson; Andrew R Harrison; Linda K McLoon; Michael S Lee
Journal:  J Neuroophthalmol       Date:  2010-06       Impact factor: 3.042

7.  Clinical experience with interferon alfa-2a for exudative age-related macular degeneration.

Authors:  J N Kirkpatrick; A D Dick; J V Forrester
Journal:  Br J Ophthalmol       Date:  1993-12       Impact factor: 4.638

8.  Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis.

Authors:  I Kötter; M Zierhut; A K Eckstein; R Vonthein; T Ness; I Günaydin; B Grimbacher; S Blaschke; W Meyer-Riemann; H H Peter; N Stübiger
Journal:  Br J Ophthalmol       Date:  2003-04       Impact factor: 4.638

9.  Treatment of ocular symptoms of Behçet's disease with interferon alpha 2a: a pilot study.

Authors:  I Kötter; A K Eckstein; N Stübiger; M Zierhut
Journal:  Br J Ophthalmol       Date:  1998-05       Impact factor: 4.638

10.  Severe course of cutaneous melanoma associated paraneoplastic retinopathy.

Authors:  U Kellner; N Bornfeld; M H Foerster
Journal:  Br J Ophthalmol       Date:  1995-08       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.